$1.62
2.22% today
Nasdaq, Apr 03, 06:44 pm CET
ISIN
CA29668H7085
Symbol
EPIX
Sector
Industry

ESSA Pharma Inc Stock price

$1.58
-0.08 4.82% 1M
-4.48 73.93% 6M
-0.21 11.73% YTD
-6.62 80.73% 1Y
-6.01 79.18% 3Y
-2.22 58.42% 5Y
-128.15 98.78% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.02 1.28%
ISIN
CA29668H7085
Symbol
EPIX
Sector
Industry

Key metrics

Market capitalization $70.13m
Enterprise Value $-50.11m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF 2.24
P/B ratio (TTM) P/B ratio 0.59
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-36.51m
Free Cash Flow (TTM) Free Cash Flow $-22.35m
Cash position $120.55m
EPS (TTM) EPS $-0.70
P/E forward negative
Short interest 1.84%
Show more

Is ESSA Pharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

ESSA Pharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a ESSA Pharma Inc forecast:

2x Hold
100%

Analyst Opinions

2 Analysts have issued a ESSA Pharma Inc forecast:

Hold
100%

Financial data from ESSA Pharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 0.08 0.08
33% 33%
-
-0.08 -0.08
33% 33%
-
- Selling and Administrative Expenses 15 15
46% 46%
-
- Research and Development Expense 21 21
0% 0%
-
-36 -36
15% 15%
-
- Depreciation and Amortization 0.08 0.08
33% 33%
-
EBIT (Operating Income) EBIT -37 -37
15% 15%
-
Net Profit -31 -31
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about ESSA Pharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

ESSA Pharma Inc Stock News

Neutral
Business Wire
9 days ago
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers and acquirers of ESSA Pharma Inc. (NASDAQ: EPIX) securities between December 12, 2023 and October 31, 2024, inclusive (the “Class Period”). The lawsuit describes ESSA as a “clinical stage pharmaceutical company that focuses on the development of...
Neutral
GlobeNewsWire
10 days ago
Investors can contact the law firm at no cost to learn more about recovering their losses
Neutral
GlobeNewsWire
11 days ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In ESSA Pharma To Contact Him Directly To Discuss Their Options
More ESSA Pharma Inc News

Company Profile

ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

Head office Canada
CEO David Parkinson
Employees 35
Founded 2009
Website www.essapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today